Show simple item record

dc.contributor.authorLinter, Katie
dc.date.accessioned2023-03-21T14:45:38Z
dc.date.available2023-03-21T14:45:38Z
dc.date.issued2021-10-05
dc.identifier.citationNorrish, G., Rance, T., Montanes, E., Field, E., Brown, E., Bhole, V., Stuart, G., Uzun, O., McLeod, K. A., Ilina, M., Adwani, S., Daubeney, P., Delle Donne, G., Linter, K., Jones, C. B., Bharucha, T., Cervi, E., & Kaski, J. P. (2022). Friedreich's ataxia-associated childhood hypertrophic cardiomyopathy: a national cohort study. Archives of disease in childhood, 107(5), 450–455. https://doi.org/10.1136/archdischild-2021-322455en_US
dc.identifier.other10.1136/archdischild-2021-322455
dc.identifier.urihttp://hdl.handle.net/20.500.12904/16541
dc.description.abstractObjective: Hypertrophic cardiomyopathy (HCM) is an important predictor of long-term outcomes in Friedreich's ataxia (FA), but the clinical spectrum and survival in childhood is poorly described. This study aimed to describe the clinical characteristics of children with FA-HCM. Design and setting: Retrospective, longitudinal cohort study of children with FA-HCM from the UK. Patients: 78 children (<18 years) with FA-HCM diagnosed over four decades. Intervention: Anonymised retrospective demographic and clinical data were collected from baseline evaluation and follow-up. Main outcome measures: The primary study end-point was all-cause mortality (sudden cardiac death, atrial arrhythmia-related death, heart failure-related death, non-cardiac death) or cardiac transplantation. Results: The mean age at diagnosis of FA-HCM was 10.9 (±3.1) years. Diagnosis was within 1 year of cardiac referral in 34 (65.0%) patients, but preceded the diagnosis of FA in 4 (5.3%). At baseline, 65 (90.3%) had concentric left ventricular hypertrophy and 6 (12.5%) had systolic impairment. Over a median follow-up of 5.1 years (IQR 2.4-7.3), 8 (10.5%) had documented supraventricular arrhythmias and 8 (10.5%) died (atrial arrhythmia-related n=2; heart failure-related n=1; non-cardiac n=2; or unknown cause n=3), but there were no sudden cardiac deaths. Freedom from death or transplantation at 10 years was 80.8% (95% CI 62.5 to 90.8). Conclusions: This is the largest cohort of childhood FA-HCM reported to date and describes a high prevalence of atrial arrhythmias and impaired systolic function in childhood, suggesting early progression to end-stage disease. Overall mortality is similar to that reported in non-syndromic childhood HCM, but no patients died suddenly.
dc.description.urihttps://adc.bmj.com/content/107/5/450en_US
dc.language.isoenen_US
dc.subjectCardiologyen_US
dc.subjectNeurologyen_US
dc.subjectPaediatricsen_US
dc.titleFriedreich's ataxia-associated childhood hypertrophic cardiomyopathy: a national cohort studyen_US
dc.typeArticleen_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US
rioxxterms.versionNAen_US
rioxxterms.versionofrecordhttp://dx.doi.org/10.1136/archdischild-2021-322455en_US
rioxxterms.typeJournal Article/Reviewen_US
refterms.panelUnspecifieden_US
html.description.abstractObjective: Hypertrophic cardiomyopathy (HCM) is an important predictor of long-term outcomes in Friedreich's ataxia (FA), but the clinical spectrum and survival in childhood is poorly described. This study aimed to describe the clinical characteristics of children with FA-HCM. Design and setting: Retrospective, longitudinal cohort study of children with FA-HCM from the UK. Patients: 78 children (<18 years) with FA-HCM diagnosed over four decades. Intervention: Anonymised retrospective demographic and clinical data were collected from baseline evaluation and follow-up. Main outcome measures: The primary study end-point was all-cause mortality (sudden cardiac death, atrial arrhythmia-related death, heart failure-related death, non-cardiac death) or cardiac transplantation. Results: The mean age at diagnosis of FA-HCM was 10.9 (±3.1) years. Diagnosis was within 1 year of cardiac referral in 34 (65.0%) patients, but preceded the diagnosis of FA in 4 (5.3%). At baseline, 65 (90.3%) had concentric left ventricular hypertrophy and 6 (12.5%) had systolic impairment. Over a median follow-up of 5.1 years (IQR 2.4-7.3), 8 (10.5%) had documented supraventricular arrhythmias and 8 (10.5%) died (atrial arrhythmia-related n=2; heart failure-related n=1; non-cardiac n=2; or unknown cause n=3), but there were no sudden cardiac deaths. Freedom from death or transplantation at 10 years was 80.8% (95% CI 62.5 to 90.8). Conclusions: This is the largest cohort of childhood FA-HCM reported to date and describes a high prevalence of atrial arrhythmias and impaired systolic function in childhood, suggesting early progression to end-stage disease. Overall mortality is similar to that reported in non-syndromic childhood HCM, but no patients died suddenly.en_US
rioxxterms.funder.project94a427429a5bcfef7dd04c33360d80cden_US


This item appears in the following Collection(s)

Show simple item record